MAPT and Alzheimer disease: Tau protein, known to increase gradually with age from <300 pg/mL (21–50 years) to almost <500 (>71 years), demonstrates a significant exponential increase in AD sufferers from >450 to >600 pg/mL (in age rage 51–70), hence proving to be a good prognostic biomarker [119].